Sorry Rappers, page-117

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 117 Last

Share
Profile

Follow
Sabre1973

1,474 Posts.

140

11/08/17

16:51

Post #: 26447574
Share

Originally posted by RNClarke ↑

Sold out the last of my holdings this morning still trying to comprehend how these trials were so poorly conducted and at such a low standard which is beyond belief.

Management can blame the hospitals and the CRO who were running the trials all they like - but it is ultimately their ineptitude which has lead to this disaster. To top it all off we have found out Australian clinical trials have not been running to even the TGA's standard.

It is unbelievable that holders who had put their faith for 10+ months were given less than 30mins to digest top line data before ResApp opened from suspension. There was no rush to come out of voluntary suspension - Many screwed their exits.

Gutsy move by Chris N adding to his position. He was a Top 20 shareholder leading into results and had put his family money on the line.

The posters on here have turned over just like the register. Very sad for the entire Sydney ResApp faithful in particular @Red bar @pj had @Lefevre @yysy @whitehorse @gothechooks and any others I have missed. I am sure we will touch base at future events but not at any ResApp presentations. A learning curve for those of us who were hosed, plenty of other great stocks with products that actually work.

All the best.

Expand

Gutted too mate. My family has bailed with massive loses, close to 600k.
This is a disgrace and the ASX should be investigating.
I will be having a word to a close friend who is an investigator there.
See you on EPT, tech that actually works
VPO

RAP Price at posting: 8.8¢ Sentiment: None Disclosure: Not Held
10 Upvote

0 Great analysis

Reply

Top Stories

DRE

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Failure to report prompts ASX to impose multiple company suspensions

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals